The role of fedratinib for the treatment of patients with primary or secondary myelofibrosis
Myelofibrosis (MF) is a chronic myeloid neoplasm characterized by either primary myelofibrosis, or secondary MF following essential thrombocythemia or polycythemia vera. Historically, therapy has been symptom directed; however, in 2011, the first janus kinase inhibitor (JAK-i) – ruxolitinib – was ap...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2020-05-01
|
| Series: | Therapeutic Advances in Hematology |
| Online Access: | https://doi.org/10.1177/2040620720925201 |
| _version_ | 1819044455193247744 |
|---|---|
| author | Jeanne Palmer Ruben Mesa |
| author_facet | Jeanne Palmer Ruben Mesa |
| author_sort | Jeanne Palmer |
| collection | DOAJ |
| description | Myelofibrosis (MF) is a chronic myeloid neoplasm characterized by either primary myelofibrosis, or secondary MF following essential thrombocythemia or polycythemia vera. Historically, therapy has been symptom directed; however, in 2011, the first janus kinase inhibitor (JAK-i) – ruxolitinib – was approved for treatment. This medication was found to be effective in reduction of symptom burden and spleen size; however, the median duration of response is about 3 years. In addition, many patients are intolerant or develop toxicities to ruxolitinib, including patients with anemia, as well as thrombocytopenia. Therefore, there is a critical need for alternate therapeutic options for patients with MF. Additional JAK-i have been developed over the last 8 years, including fedratinib, momelotinib, and pacritinib. Fedratinib recently received approval for treatment of MF both in the first-line and second-line setting. It has shown efficacy in the first-line setting, as well as in 30% of patients who are refractory/intolerant of ruxolitinib. This review covers the trials that have led to the approval of ruxolitinib as well as fedratinib, as well as reviews of two JAK inhibitors that are still under clinical investigation: momelotinib and pacritinib. |
| first_indexed | 2024-12-21T10:12:57Z |
| format | Article |
| id | doaj.art-a38a4922ef5c43d7a6b925fac1864222 |
| institution | Directory Open Access Journal |
| issn | 2040-6215 |
| language | English |
| last_indexed | 2024-12-21T10:12:57Z |
| publishDate | 2020-05-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Hematology |
| spelling | doaj.art-a38a4922ef5c43d7a6b925fac18642222022-12-21T19:07:39ZengSAGE PublishingTherapeutic Advances in Hematology2040-62152020-05-011110.1177/2040620720925201The role of fedratinib for the treatment of patients with primary or secondary myelofibrosisJeanne PalmerRuben MesaMyelofibrosis (MF) is a chronic myeloid neoplasm characterized by either primary myelofibrosis, or secondary MF following essential thrombocythemia or polycythemia vera. Historically, therapy has been symptom directed; however, in 2011, the first janus kinase inhibitor (JAK-i) – ruxolitinib – was approved for treatment. This medication was found to be effective in reduction of symptom burden and spleen size; however, the median duration of response is about 3 years. In addition, many patients are intolerant or develop toxicities to ruxolitinib, including patients with anemia, as well as thrombocytopenia. Therefore, there is a critical need for alternate therapeutic options for patients with MF. Additional JAK-i have been developed over the last 8 years, including fedratinib, momelotinib, and pacritinib. Fedratinib recently received approval for treatment of MF both in the first-line and second-line setting. It has shown efficacy in the first-line setting, as well as in 30% of patients who are refractory/intolerant of ruxolitinib. This review covers the trials that have led to the approval of ruxolitinib as well as fedratinib, as well as reviews of two JAK inhibitors that are still under clinical investigation: momelotinib and pacritinib.https://doi.org/10.1177/2040620720925201 |
| spellingShingle | Jeanne Palmer Ruben Mesa The role of fedratinib for the treatment of patients with primary or secondary myelofibrosis Therapeutic Advances in Hematology |
| title | The role of fedratinib for the treatment of patients with primary or secondary myelofibrosis |
| title_full | The role of fedratinib for the treatment of patients with primary or secondary myelofibrosis |
| title_fullStr | The role of fedratinib for the treatment of patients with primary or secondary myelofibrosis |
| title_full_unstemmed | The role of fedratinib for the treatment of patients with primary or secondary myelofibrosis |
| title_short | The role of fedratinib for the treatment of patients with primary or secondary myelofibrosis |
| title_sort | role of fedratinib for the treatment of patients with primary or secondary myelofibrosis |
| url | https://doi.org/10.1177/2040620720925201 |
| work_keys_str_mv | AT jeannepalmer theroleoffedratinibforthetreatmentofpatientswithprimaryorsecondarymyelofibrosis AT rubenmesa theroleoffedratinibforthetreatmentofpatientswithprimaryorsecondarymyelofibrosis AT jeannepalmer roleoffedratinibforthetreatmentofpatientswithprimaryorsecondarymyelofibrosis AT rubenmesa roleoffedratinibforthetreatmentofpatientswithprimaryorsecondarymyelofibrosis |